158 research outputs found
Tuberculosis infection in a patient treated with Nivolumab for non-small cell lung cancer : case report and literature review
Nivolumab (PD-1 inhibitor) and other immune checkpoint inhibitors are used primarily
to promote reactivation of anti-tumor immunity. However, due to their generalized
immunorestorative properties, these agents may also trigger an unusual spectrum
of side-effects termed immune-related adverse events. In the case of the lung,
pulmonary infiltrates in patients treated with the anti-PD-1 inhibitors, nivolumab,
or pembrolizumab, especially patients with non-small cell lung cancer, can result
from immune-related pneumonitis, which, until fairly recently was believed to be of
non-infective origin. This, in turn, may result in progression and pseudo-progression of
disease. An increasing body of evidence has, however, identified pulmonary tuberculosis
as an additional type of anti-PD-1 therapy-associated, immune-related adverse event,
seemingly as a consequence of excessive reactivation of immune responsiveness to
latentMycobacteriumtuberculosis infection. The current case report describes a 56-year
old Caucasian female who presented with microbiologically-confirmed tuberculosis
infection while on nivolumab therapy for non-small cell lung cancer. Notably, the
patient, seemingly the first described from the African Continent, had not received
immunosuppressive therapy prior to the diagnosis of tuberculosis.http://www.frontiersin.org/Oncologyam2020Immunolog
Breakdown of the lattice polaron picture in La0.7Ca0.3MnO3 single crystals
When heated through the magnetic transition at Tc, La0.7Ca0.3MnO3 changes
from a band metal to a polaronic insulator. The Hall constant R_H, through its
activated behavior and sign anomaly, provides key evidence for polaronic
behavior. We use R_H and the Hall mobility to demonstrate the breakdown of the
polaron phase. Above 1.4Tc, the polaron picture holds in detail, while below,
the activation energies of both R_H and the mobility deviate strongly from
their polaronic values. These changes reflect the presence of metallic,
ferromagnetic fluctuations, in the volume of which the Hall effect develops
additional contributions tied to quantal phases.Comment: 11 pages, 3 figures, final version to appear in Phys. Rev. B Rapi
High mobility group box 1 in human cancer
High mobility group box 1 (HMGB1) is an extremely versatile protein that is located
predominantly in the nucleus of quiescent eukaryotic cells, where it is critically involved in maintaining
genomic structure and function. During cellular stress, however, this multifaceted, cytokine-like
protein undergoes posttranslational modifications that promote its translocation to the cytosol, from
where it is released extracellularly, either actively or passively, according to cell type and stressor.
In the extracellular milieu, HMGB1 triggers innate inflammatory responses that may be beneficial or
harmful, depending on the magnitude and duration of release of this pro-inflammatory protein at
sites of tissue injury. Heightened awareness of the potentially harmful activities of HMGB1, together
with a considerable body of innovative, recent research, have revealed that excessive production of
HMGB1, resulting from misdirected, chronic inflammatory responses, appears to contribute to all the
stages of tumorigenesis. In the setting of established cancers, the production of HMGB1 by tumor
cells per se may also exacerbate inflammation-related immunosuppression. These pro-inflammatory
mechanisms of HMGB1-orchestrated tumorigenesis, as well as the prognostic potential of detection
of elevated expression of this protein in the tumor microenvironment, represent the major thrusts of
this review.http://www.mdpi.com/journal/cellspm2020Immunolog
Tumor-Infiltrating lymphocytes (TILs) in early breast cancer patients: high CD3+ , CD8+ , and Immunoscore are associated with a pathological complete response
BACKGROUND : Tumor-infiltrating lymphocytes are associated with a better prognosis in early triple-negative breast cancer (TNBC). These cells can be enumerated in situ by the “Immunoscore Clinical Research” (ISCR). The original Immunoscore® is a prognostic tool that categorizes the densities of CD3+ and CD8+ cells in both the invasive margin (IM) and center of the tumor (CT) in localized colon cancer, yielding a five-tiered classification (0–4). We evaluated the prognostic potential of ISCR and pathological complete response (pCR) following neoadjuvant chemotherapy (NACT). METHODS : The cohort included 53 TNBC, 32 luminal BC, and 18 HER2-positive BC patients undergoing NACT. Pre-treatment tumor biopsies were immune-stained for CD3+ and CD8+ T-cell markers. Quantitative analysis of these cells in different tumor locations was performed using computer-assisted image analysis. RESULTS : The pCR rate was 44%. Univariate analysis showed that primary tumor size, estrogen-receptor negative, progesteronereceptor negative, luminal vs. HER2-positive vs. TNBC, high Ki-67, high densities (cells/mm2 ) of CD3 CT, CD8+ CT, CD3+ IM, and CD8+ IM cells were associated with a high pCR. ISCR was associated with pCR following NACT. A multivariate model consisting of ISCR and the significant variables from the univariate analysis showed a significant trend for ISCR; however, the low sample size did not provide enough power for the model to be included in this study. CONCLUSIONS : These results revealed a significant prognostic role for the spatial distributions of the CD3+ , and CD8+ lymphocytes, as well as the ISCR in relation to pCR following NACT.Medical Oncology Centre
of Rosebankhttps://www.mdpi.com/journal/cancersdm2022Immunolog
Systemic immune dysregulation in early breast cancer is associated with decreased plasma levels of both soluble co-inhibitory and co-stimulatory immune checkpoint molecules
Breast cancer cells exploit the up-regulation or down-regulation of immune checkpoint
proteins to evade anti-tumor immune responses. To explore the possible involvement of
this mechanism in promoting systemic immunosuppression, the pre-treatment levels of
soluble co-inhibitory and co-stimulatory immune checkpoint molecules, as well as those
of cytokines, chemokines, and growth factors were measured in 98 newly diagnosed
breast cancer patients and compared with those of 45 healthy controls using multiplex
bead array and ELISA technologies. Plasma concentrations of the co-stimulatory immune
checkpoints, GITR, GITRL, CD27, CD28, CD40, CD80, CD86 and ICOS, as well as the
co-inhibitory molecules, PD-L1, CTLA-4 and TIM-3, were all significantly lower in early
breast cancer patients compared to healthy controls, as were those of HVEM and sTLR-2,
whereas the plasma concentrations of CX3CL1 (fractalkine), CCL5 (RANTES) and those
of the growth factors, M-CSF, FGF-21 and GDF-15 were significantly increased.
However, when analyzed according to the patients’ breast cancer characteristics, these
being triple negative breast cancer (TNBC) vs. non-TNBC, tumor size, stage, nodal status
and age, no significant differences were detected between the plasma levels of the various
immune checkpoint molecules, cytokines, chemokines and growth factors. Additionally,
none of these biomarkers correlated with pathological complete response. This study has
identified low plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint
molecules in newly diagnosed, non-metastatic breast cancer patients compared to
healthy controls, which is a novel finding seemingly consistent with a state of systemic
immune dysregulation. Plausible mechanisms include an association with elevated levels
of M-CSF and CCL5, implicating the involvement of immune suppressor cells of the M2-macrophage/monocyte phenotype as possible drivers of this state of systemic
immune quiescence/dysregulation.The Cancer Association of South Africa (CANSA).https://www.frontiersin.org/journals/immunologydm2022Immunolog
Hundreds of variants clustered in genomic loci and biological pathways affect human height
Most common human traits and diseases have a polygenic pattern of inheritance: DNA sequence variants at many genetic loci influence the phenotype. Genome-wide association (GWA) studies have identified more than 600 variants associated with human traits, but these typically explain small fractions of phenotypic variation, raising questions about the use of further studies. Here, using 183,727 individuals, we show that hundreds of genetic variants, in at least 180 loci, influence adult height, a highly heritable and classic polygenic trait. The large number of loci reveals patterns with important implications for genetic studies of common human diseases and traits. First, the 180 loci are not random, but instead are enriched for genes that are connected in biological pathways (P = 0.016) and that underlie skeletal growth defects (P < 0.001). Second, the likely causal gene is often located near the most strongly associated variant: in 13 of 21 loci containing a known skeletal growth gene, that gene was closest to the associated variant. Third, at least 19 loci have multiple independently associated variants, suggesting that allelic heterogeneity is a frequent feature of polygenic traits, that comprehensive explorations of already-discovered loci should discover additional variants and that an appreciable fraction of associated loci may have been identified. Fourth, associated variants are enriched for likely functional effects on genes, being over-represented among variants that alter amino-acid structure of proteins and expression levels of nearby genes. Our data explain approximately 10% of the phenotypic variation in height, and we estimate that unidentified common variants of similar effect sizes would increase this figure to approximately 16% of phenotypic variation (approximately 20% of heritable variation). Although additional approaches are needed to dissect the genetic architecture of polygenic human traits fully, our findings indicate that GWA studies can identify large numbers of loci that implicate biologically relevant genes and pathways.
The succession of Vertebratesand Plants across the Cretaceous-Tertiary boundary in the Tremp Formation, Ager valley (South-central Pyrenees, Spain)
Anisotropic Magnetoresistance Effects in Fe, Co, Ni, Fe_4N, and Half-Metallic Ferromagnet: A Systematic Analysis
We theoretically analyze the anisotropic magnetoresistance (AMR) effects of
bcc Fe (+), fcc Co (+), fcc Ni (+), FeN (-), and a half-metallic
ferromagnet (-). The sign in each ( ) represents the sign of the AMR ratio
observed experimentally. We here use the two-current model for a system
consisting of a spin-polarized conduction state and localized d states with
spin--orbit interaction. From the model, we first derive a general expression
of the AMR ratio. The expression consists of a resistivity of the conduction
state of the spin ( or ), , and resistivities due to s--d scattering processes from the
conduction state to the localized d states. On the basis of this expression, we
next find a relation between the sign of the AMR ratio and the s--d scattering
process. In addition, we obtain expressions of the AMR ratios appropriate to
the respective materials. Using the expressions, we evaluate their AMR ratios,
where the expressions take into account the values of of the respective materials. The evaluated AMR
ratios correspond well to the experimental results.Comment: 17 pages, 12 figures, to be published in J. Phys. Soc. Jpn, minor
mistakes corrected, final versio
A prospective, real‑world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN : a MASCC neutropenia, infection, and myelosuppression study group initiative
DATA AVAILABILITY : Novartis supports the publication of scientifically rigorous analysis that is relevant to patient care, regardless of a positive or negative outcome. Qualified external researchers can request access to anonymized patient-level data, respecting patient-informed consent, through www. clini calst udyda tareq uest. com, according to requirements noted on the web portal.PURPOSE : Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10–20%) of FN would develop ≥ 1 episode of FN with a commonly used chemotherapy regimen in clinical practice. METHODS : This prospective, real-world, observational, multinational, multicenter study (December 2016–October 2019) recruited patients with solid tumors or Hodgkin’s/non-Hodgkin’s lymphoma. Patients receiving chemotherapy with intermediate risk of FN, but not G-CSF as primary prophylaxis were included and observed for the duration of the chemotherapy (≤ 6 cycles and ≤ 30 days after the last chemotherapy administration). RESULTS : In total, 364 patients (median age, 56 years) with 1601 cycles of chemotherapy were included in the analysis. The incidence of FN was 5% in cycle 1, 3% in cycles 2–3, and 1% in cycles 4–6. The rate of patients with ≥ 1 episode of FN was 9%, and 59% of FN events were reported during cycle 1. The rate of grade 4 neutropenia in cycle 1 was 11%, and 15% of patients experienced ≥ 1 episode of grade 4 neutropenia. CONCLUSIONS : Overall, the incidence of FN was low, with a high incidence in cycle 1 and a decrease in the subsequent cycles. These results provide the real FN risk for common chemotherapy regimens in patients generally excluded from clinical trials. Prophylactic G-CSF in intermediate-risk patients could be considered as per clinician’s judgement.Open access funding provided by University of Pretoria. This
work was supported by research funding from Novartis Pharma AG,
Basel, Switzerland.https://www.springer.com/journal/520am2024ImmunologySDG-03:Good heatlh and well-bein
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early breast cancer (BC), potentially setting the scene for more effective implementation of checkpoint-targeted immunotherapy. This issue has been investigated in the current study in which alterations in the plasma concentrations of 16 soluble co-stimulatory and co-inhibitory, immune checkpoints were measured sequentially in a cohort of newly diagnosed, early BC patients (n=72), pre-treatment, post-NAC and post-surgery using a Multiplex® bead array platform. Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). Following NAC, the plasma levels of six soluble co-stimulatory checkpoints (CD28, CD40, ICOS, CD27, CD80, GITR), all involved in activation of CD8+ cytotoxic T cells, were significantly increased (p<0.04-p<0.00001), comparable with control values and remained at these levels post-surgery. Of the soluble co-inhibitory checkpoints, three (LAG-3, PD-L1, TIM-3) increased significantly post-NAC, reaching levels significantly greater than those of the control group. PD-1 remained unchanged, while BTLA and CTLA-4 decreased significantly (p<0.03 and p<0.00001, respectively). Normalization of soluble co-stimulatory immune checkpoints is seemingly indicative of reversal of systemic immune dysregulation following administration of NAC in early BC, while recovery of immune homeostasis may explain the increased levels of several negative checkpoint proteins, albeit with the exceptions of CTLA-4 and PD-1. Although a pathological complete response (pCR) was documented in 61% of patients (mostly triple-negative BC), surprisingly, none of the soluble immune checkpoints correlated with the pCR, either pre-treatment or post-NAC. Nevertheless, in the case of the co-stimulatory ICMs, these novel findings are indicative of the immune-restorative potential of NAC in early BC, while in the case of the co-inhibitory ICMs, elevated levels of soluble PD-L1, LAG-3 and TIM-3 post-NAC underscore the augmentative immunotherapeutic promise of targeting these molecules, either individually or in combination, as a strategy, which may contribute to the improved management of early BC
- …